an associate professor at the Winship Cancer Institute of Emory University
Teclistamab Transforms Early Myeloma Care: Roberto Mina, MD
The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple myeloma, explained Roberto Mina, MD.